Literature DB >> 31178611

Bayesian Hierarchical Varying-sparsity Regression Models with Application to Cancer Proteogenomics.

Yang Ni1, Francesco C Stingo2, Min Jin Ha3, Rehan Akbani4, Veerabhadran Baladandayuthapani3.   

Abstract

Identifying patient-specific prognostic biomarkers is of critical importance in developing personalized treatment for clinically and molecularly heterogeneous diseases such as cancer. In this article, we propose a novel regression framework, Bayesian hierarchical varying-sparsity regression (BEHAVIOR) models to select clinically relevant disease markers by integrating proteogenomic (proteomic+genomic) and clinical data. Our methods allow flexible modeling of protein-gene relationships as well as induces sparsity in both protein-gene and protein-survival relationships, to select ge-nomically driven prognostic protein markers at the patient-level. Simulation studies demonstrate the superior performance of BEHAVIOR against competing method in terms of both protein marker selection and survival prediction. We apply BEHAV-IOR to The Cancer Genome Atlas (TCGA) proteogenomic pan-cancer data and find several interesting prognostic proteins and pathways that are shared across multiple cancers and some that exclusively pertain to specific cancers.

Entities:  

Keywords:  Prognostic biomarker; p-splines; precision medicine; threshold; tumor heterogeneity

Year:  2018        PMID: 31178611      PMCID: PMC6552682          DOI: 10.1080/01621459.2018.1434529

Source DB:  PubMed          Journal:  J Am Stat Assoc        ISSN: 0162-1459            Impact factor:   5.033


  45 in total

1.  From molecular to modular cell biology.

Authors:  L H Hartwell; J J Hopfield; S Leibler; A W Murray
Journal:  Nature       Date:  1999-12-02       Impact factor: 49.962

Review 2.  Computational systems biology.

Authors:  Hiroaki Kitano
Journal:  Nature       Date:  2002-11-14       Impact factor: 49.962

3.  Proteogenomic mapping as a complementary method to perform genome annotation.

Authors:  Jacob D Jaffe; Howard C Berg; George M Church
Journal:  Proteomics       Date:  2004-01       Impact factor: 3.984

4.  Wnt/beta-catenin signaling inhibits death receptor-mediated apoptosis and promotes invasive growth of HNSCC.

Authors:  Fan Yang; Qinghua Zeng; Guangyan Yu; Shenglin Li; Cun-Yu Wang
Journal:  Cell Signal       Date:  2005-08-09       Impact factor: 4.315

Review 5.  New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway.

Authors:  L C Cantley; B G Neel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

6.  Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front.

Authors:  C P Paweletz; L Charboneau; V E Bichsel; N L Simone; T Chen; J W Gillespie; M R Emmert-Buck; M J Roth; E F Petricoin III; L A Liotta
Journal:  Oncogene       Date:  2001-04-12       Impact factor: 9.867

7.  Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.

Authors:  Fan Lin; Ping L Zhang; Ximing J Yang; Jeffrey W Prichard; Mingyue Lun; Robert E Brown
Journal:  Ann Clin Lab Sci       Date:  2006       Impact factor: 1.256

8.  Correlation between protein and mRNA abundance in yeast.

Authors:  S P Gygi; Y Rochon; B R Franza; R Aebersold
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

9.  Contributions of ATM mutations to familial breast and ovarian cancer.

Authors:  Yvonne R Thorstenson; Adriane Roxas; Regina Kroiss; Mark A Jenkins; Kristine M Yu; Thomas Bachrich; Daniela Muhr; Tierney L Wayne; Gilbert Chu; Ronald W Davis; Teresa M U Wagner; Peter J Oefner
Journal:  Cancer Res       Date:  2003-06-15       Impact factor: 12.701

10.  Conventional (clear cell) renal carcinoma metastases have greater bcl-2 expression than high-risk primary tumors.

Authors:  Cheryl T Lee; Elizabeth M Genega; Brian Hutchinson; Paul A Fearn; Michael W Kattan; Paul Russo; Victor E Reuter
Journal:  Urol Oncol       Date:  2003 May-Jun       Impact factor: 3.498

View more
  5 in total

Review 1.  Challenges and Opportunities for Bayesian Statistics in Proteomics.

Authors:  Oliver M Crook; Chun-Wa Chung; Charlotte M Deane
Journal:  J Proteome Res       Date:  2022-03-08       Impact factor: 4.466

Review 2.  Bayesian graphical models for modern biological applications.

Authors:  Yang Ni; Veerabhadran Baladandayuthapani; Marina Vannucci; Francesco C Stingo
Journal:  Stat Methods Appt       Date:  2021-05-27

3.  Tumor heterogeneity estimation for radiomics in cancer.

Authors:  Ani Eloyan; Mun Sang Yue; Davit Khachatryan
Journal:  Stat Med       Date:  2020-09-23       Impact factor: 2.373

Review 4.  The Application of Bayesian Methods in Cancer Prognosis and Prediction.

Authors:  Jiadong Chu; N A Sun; Wei Hu; Xuanli Chen; Nengjun Yi; Yueping Shen
Journal:  Cancer Genomics Proteomics       Date:  2022 Jan-Feb       Impact factor: 4.069

5.  Drug sensitivity prediction with normal inverse Gaussian shrinkage informed by external data.

Authors:  Magnus M Münch; Mark A van de Wiel; Sylvia Richardson; Gwenaël G R Leday
Journal:  Biom J       Date:  2020-07-23       Impact factor: 1.715

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.